LCB73

LCB73 is an experimental CD19-targeted antibody-drug conjugate (ADC) for B‑cell hematologic malignancies, created by combining a human monoclonal antibody against the B‑cell antigen CD19 with LegoChem Biosciences’ cancer‑selectively activated next‑generation linker and a pyrrolobenzodiazepine (PBD) dimer prodrug payload. Upon intravenous administration, the antibody moiety binds CD19 on malignant B cells, the conjugate is internalized, and the tumor‑cleavable beta‑glucuronide linker and PBD prodrug are selectively processed by lysosomal beta‑glucuronidase overexpressed in tumor cells, releasing free PBD that forms highly cytotoxic DNA interstrand cross‑links to block cell division and induce apoptosis in CD19‑positive cells.[7][5][2] LCB73 (also known as IKS03/NI‑2201) was generated through a partnership between Light Chain Bioscience (formerly Novimmune) and LegoChem Biosciences, and is being clinically developed by Iksuda Therapeutics for difficult‑to‑treat B‑cell cancers such as diffuse large B‑cell lymphoma, aggressive B‑cell non‑Hodgkin lymphoma, acute lymphoblastic leukemia, and Burkitt lymphoma.[3][1][10]

Other names

anti-CD19 antibody-drug conjugate IKS03anti-CD-19 antibody-drug conjugate IKS03anti-CD 19 antibody-drug conjugate IKS03anti-CD19 ADC IKS03anti-CD-19 ADC IKS03anti-CD 19 ADC IKS03anti-CD19/PBD ADC IKS03CD19 ADCCD-19 ADCCD 19 ADC